PepGen Faces Legal Storm Over Drug Trial Debacle

In a dramatic turn of events, PepGen Inc. finds itself at the center of a significant legal battle as shareholders rally against the biotech company. The lawsuit, filed as a class action, accuses PepGen of misleading investors about the efficacy and safety of its flagship drug candidate, PGN-EDO51. Between March 7, 2024, and March 3, 2025, shareholders allege that PepGen’s public statements painted an overly optimistic picture of the drug’s potential, leading to financial losses when the truth came to light.

The crux of the complaint lies in claims that PepGen’s management made false statements regarding the CONNECT2 study, a critical phase two trial for PGN-EDO51. According to the lawsuit, the study was fraught with issues that jeopardized its approval by the FDA, casting doubt on the drug’s clinical and commercial viability. These revelations have prompted shareholders to seek redress for the financial impact of these alleged misrepresentations.

For those who have experienced losses in PepGen stock during the specified period, there is an opportunity to join the lawsuit and potentially recover damages. Interested parties are encouraged to visit the provided link to understand their rights and the steps involved in seeking recovery. Importantly, there is no cost or obligation to participate in this legal action.

With a reputation for securing substantial settlements for investors, the law firm Levi & Korsinsky LLP is spearheading the case. Known for their expertise in securities litigation, the firm has been a formidable force in the legal arena, consistently ranking among the top in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Home